CYP2B6 and CYP2C19 phenotypes of the patients were established on the basis of their genotypes, whereas the patients’ response to anticancer therapy was defined as responders (complete remission and partial remission, N = 24/50) and non-responders (stable disease and progressive disease/exit, N = 26/50) on the basis of the primary tumour response (Tables 1 and 2). Here, CYP2C19 is linked to neoplasm.